The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.
While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...
The Promega OncoMate® MSI Dx Analysis System has received FDA approval as a companion diagnostic for KEYTRUDA® plus LENVIMA® ...
Merck & Co. has won European Commission approval of a formulation of its blockbuster cancer drug Keytruda that can be injected under the skin. The Rahway, N.J., drugmaker on Wednesday said the green ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics ...
The FDA has prioritized reviewing Padcev and Keytruda for MIBC patients ineligible for cisplatin chemotherapy, with a target action date of April 7, 2026. Phase 3 EV-303 trial results showed a 60% ...
This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...
Merck announces EC approves SC administration of Keytruda for all adult indications approved in the European Union: Rahway, New Jersey Thursday, November 20, 2025, 14:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback